gip and glp 1 drugs Frontiers The GLP-1 revolution: What UAB
Description
Brazeau, P
Obesity and endothelial function
Mazzolai L, Teixido-Tura G, Lanzi S, et al
The SGLT2 Comparison Was More Complicated The comparison against SGLT2 inhibitors is especially valuable because it places GLP-1 receptor agonists against another modern metabolic drug class rather than older diabetic therapies
The risk-benefit profile of triple agonists remains under investigation
this risk is known to increase with age, and is more common in women (1.5 times compared with men) ( In an AD mouse model, GLP-1RAs were demonstrated to reduce the levels of AD pathological markers, including oligomeric antibodies and antibody plaque load, reduce the activation of microglia, and improve memory behavior ( 2+ and hypoxia
